Micar21.com is a drug discovery factory
  • PIPELINE
  • COMPANY
    • About us
    • Team
      • management team filip fratev
      • management team dimitar dimitrov
      • management team elina mihaylova
      • management team miguel rivera
    • Partners
    • Business model
    • Careers
    • Contact us
  • NEWS & PUBLICATIONS
    • Company news
      • Micar 21 Ltd started to provide to customers discovery of novel active substances for medicinal cosmetics development.
      • New! A pioneering study focused on the prevention of hypertrophic cardiomyopathy (HCM) among individuals with a sarcomere gene mutation (Feb. 2015)
      • Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
      • Structural and Dynamical Insight into PPARγ
      • Try our outsourcing services!
      • Identification of P-glycoprotein binders based on in house prepared diverse set of structures
      • PPARγ helix 12 exhibits an antagonist conformation
      • PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
      • Micar Innovation (Micar21) TOP 8 BioTech Award by Delta Ventures and the TOP 50 of the 2018 Startup World Cup & Summit Regional Finals!
      • Diplomatic World
      • Micar Innovation listed as a Emerging Players
      • Micar Innovation is One of 250 Companies
      • Micar Innovation (Micar21) is the winner of а prestigious award for Innovative enterprise of the year 2018
      • AI for Drug Discovery Biomarker Development
      • Discovery of the first class of dual CCR5/7 antagonists for COVID-19
      • Covid B.1.1.529
    • Scientific publications
      • Combination of Genetic Screening and Molecular Dynamics as a Useful Tool for Identification of Disease-Related Mutations: ZASP PDZ Domain G54S Mutation Case
      • Structural insight into the UNC-45–myosin complex
      • Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
      • Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study
      • Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
      • Structural and Dynamical Insight into PPARγ Antagonism: In silico Study of the Ligand-Receptor Interactions of non-Covalent Antagonists
      • Molecular dynamics simulation of the human estrogen receptor alpha: contribution to the pharmacophore of the agonists
      • PPARγ helix 12 exhibits an antagonist conformation
      • PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
      • Prediction of Accurate Binding Modes using Combination of classical and accelerated Molecular dynamics and Free Energy Perturbation Calculations: An Application to Toxicity Studies
      • An Improvement of the Free Energy Perturbation (FEP+) Sampling Protocol in Case of Flexible protein Ligand Binding Sites
      • Combination of Structural based Pharmacophore and Docking Virtual Screens: An Efficient Structure-based Protocol for Lead Identification
      • Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies
      • Discovery of New Classes of Glycine transporter 2 (GlyT2) Inhibitors and GlyT2 Selectivity Studies
      • Discovery of New AKT1 Inhibitors by Combination of In silico Structure Based Virtual Screening Approaches and Biological Evaluations
      • N501Y_mutation_manuscript
      • N501Y and K417N mutation manuscript
    • Achievements & Awards
    • Interview in the news
    • Analytics reports
    • Events

Precision genetic screen analysis by novel advanced approaches = Precision Medicine (Pharmacogenomics)

What is pharmacogenomics?

Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup.

Many drugs that are currently available are “one size fits all,” but they don't work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects (called adverse drug reactions). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body’s response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions.

The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.

Source: https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics

We bring to the ordinary people advanced information obtained by high-end technology. Based on a DNA test, we can: provide significant information about how an identified mutation alters protein structure and functions; answer at a highly sufficient level the question whether it is a disease-causing mutation or not; inform you whether existing drugs, if any, can influence your particular case (mutation); propose experimental treatment and even natural products that might help physicians in case no approved drugs exist; propose an individual project for each client;

Pharmacogenomics - Precision genetic screen analysis by novel advanced approaches

Our company has made a step forward in the genetic screen analysis, and we have recently proposed well established Molecular Dynamics (MD) methodologies in the investigation of the impact of mutations already classified as disease-causing and those classified as VOUS in the protein structure and function. MD simulations are largely employed in protein structure investigations, but they had been mostly neglected in VOUS classification till now due to their computational expenses and due to the fact that they cannot be performed automatically.

Pharmacogenomics - Precision genetic screen analysis by novel advanced approaches - Scientific information

FAQ - Pharmacogenomics - Precision genetic screen analysis: What should I send you?: We need only the genetic report obtained from the company which has performed your DNA test. Alternatively, you can email us only information about the genes and mutations which have been identified.

FAQ - Pharmacogenomics - Precision genetic screen analysis

Try our Drug Discovery Services & Prices (prices are valid for limited time). Your factory for Drug Discovery of novel compounds for the treatment of diversity diseases

Try our Drug Discovery Services

Contact

  • Micar21 (Micar Innovation)
  • 38A, Karamfil street, 1616, Sofia, Bulgaria
  • info@micar21.com
  • www.micar21.com
  • +359 888 531345 (Time zone: +2 GMT)

For Media

If you are a journalist or a media representative and would like to write about Micar21 Drug Discovery Factory or interview our founders, please contact us at: info@Micar21.com

For Partners, Collaborations and Investors

For investor, collaboration and partner inquiries, please contact Dimitar Dimitrov: dimitar@Micar21.com

HIPPA
Cookies
Research approval

Micar21 (Micar Innovation) © 2016 - 2024 All rights reserved.